Le Lézard
Classified in: Business
Subjects: OTC, ATY

AXIOM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Axiom Holdings, Inc. To Contact The Firm


NEW YORK, June 20, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Axiom Holdings, Inc. ("Axiom" or the "Company") (Other OTC: AIOM).

Faruqi & Faruqi, LLP.

The investigation focuses on whether the Company and its executives violated federal securities laws.  On June 19, 2017, in response to a Securities and Exchange Commission subpoena, the Company disclosed that it had discovered inconsistencies in its prior announcements regarding the validity of its Share Exchange Agreement (the "SEA") with CJC Holdings Ltd. ("CJC").

Then, on June 20, 2017, Axiom announced that it will be rescinding shares related to CJC reverse merger as it has started an internal investigation into the December 2016 transaction.  The Company revealed that CJC's Chief Executive Officer ("CEO") Nankamalu, who signed the SEA on behalf of CJC, had in fact already resigned as CEO a month prior to the signing and the merger was not completed.  Axiom has claimed that it will seek a court injunction to restrain such shares from being transferred until the investigation is completed.

On this news, Axiom's share price declined during intraday trading, causing harm to investors.

If you invested in Axiom stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/AIOM.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].  

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

 

SOURCE Faruqi & Faruqi, LLP


These press releases may also interest you

at 02:27
Asahi India Glass...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:12
Skanska and its joint venture partner, B. Bell Builders, have signed a contract for a new building adjacent to McNair Hall at Rice University in Houston, Texas, USA. Skanska's share of the contract is worth USD 48M, about SEK 500M, which will be...

at 02:05
CRH plc (LSE:CRH):   Key Highlights      Summary Financials Q1 2024 Change     Total revenues $6.5bn +2%     Net income $114m n/m1    ...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:42
Skanska has received a supplemental award under a contract with an existing client to build a data center in Arizona, USA. The supplemental award is worth USD 150M, about SEK 1.6 billion, which will be included in the US order bookings for the second...



News published on and distributed by: